Terence Flynn, an analyst from Morgan Stanley, maintained the Buy rating on AbbVie. The associated price target was raised to $255.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Terence Flynn has given his Buy rating due to a combination of factors that highlight AbbVie’s strong financial performance and growth potential. The company posted a solid second-quarter performance, exceeding expectations and subsequently raising its revenue and EPS guidance for 2025. This upward revision reflects confidence in the continued success of AbbVie’s key immunology products, Skyrizi and Rinvoq, which have been performing well and are expected to sustain their growth trajectory.
Additionally, AbbVie’s strategic investments in its U.S. manufacturing capabilities and its commitment to expanding production further bolster its long-term growth outlook. The company’s proactive approach to managing potential tariff impacts and its robust pipeline of products contribute to a positive assessment of its future prospects. Overall, these factors underpin Flynn’s optimistic view and justify the Buy rating for AbbVie’s stock.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $250.00 price target.